Novel drug shows promise for alleviating both heart failure and the sleep apnea associated with it

A novel drug is showing promise for alleviating heart failure, a common condition associated with sleep apnea and a reduced lifespan. The drug, known as AF-130, was tested in an animal model at Waipapa Taumata Rau, the University of Auckland where researchers found it improved the heart’s ability to pump, but, equally important, prevented sleep apnea, which itself reduces lifespan. The work is published in the journal Nature Communications.